Table 1.
UroSEEK’s component findings in the early detection cohort with equivocal urine cytology across diagnosis, grade and stage categories
| n | % | TERTSeqS | UroSeqS | FastSeqS | ||||
|---|---|---|---|---|---|---|---|---|
| Diagnosis | ||||||||
| CIS | 2 | 9 | 1 | 50% | 2 | 100% | 0 | 0% |
| LGTCC | 3 | 14 | 3 | 100% | 3 | 100% | 2 | 67% |
| HGTCC | 7 | 32 | 4 | 57% | 6 | 86% | 6 | 86% |
| INTCC | 10 | 45 | 5 | 50% | 9 | 90% | 5 | 50% |
| Grade | ||||||||
| LG | 3 | 14 | 3 | 100% | 3 | 100% | 2 | 67% |
| HG | 19 | 86 | 10 | 53% | 17 | 89% | 11 | 58% |
| Stage | ||||||||
| pTis | 2 | 9 | 1 | 50% | 2 | 100% | 0 | 0% |
| pTa | 10 | 45 | 7 | 70% | 9 | 90% | 8 | 80% |
| pT1 | 6 | 27 | 3 | 50% | 5 | 83% | 3 | 50% |
| pT2 | 2 | 9 | 1 | 50% | 2 | 100% | 1 | 50% |
| pT3 | 1 | 5 | 1 | 100% | 1 | 100% | 1 | 100% |
| pT4 | 1 | 5 | 0 | 0% | 1 | 100% | 0 | 0% |
CIS, urothelial carcinoma in situ; LGTCC, non-invasive low-grade papillary urothelial carcinoma; HGTCC, non-invasive high-grade papillary urothelial carcinoma; INTCC, infiltrating high-grade urothelial carcinoma; LG, low grade; HG, high grade
*
Histologic tumor features are not available for 3/24 cases (detected by cytology or cystoscopy)